Key result
Valsartan/hydrochlorothiazide is an efficacious fixed-dose combination antihypertensive agent that is superior to its individual components and has similar morbidity and mortality outcomes to amlodipine.
Why the study?
Does valsartan/hydrochlorothiazide improve blood pressure control and cardiovascular outcomes in hypertensive patients compared to monotherapy or amlodipine?
Does valsartan/hydrochlorothiazide improve blood pressure control and cardiovascular outcomes in hypertensive patients compared to monotherapy or amlodipine?
Valsartan/hydrochlorothiazide is an efficacious and well-tolerated fixed-dose combination for hypertension, including in high-risk subgroups.
May support valsartan/hydrochlorothiazide over monotherapy in hypertension; leaves open need for prospective outcome trials versus amlodipine.
BACKGROUND: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. OBJECTIVE: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. METHODS: Review of current literature. RESULTS: Valsartan/hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to be efficacious in such populations. CONCLUSION: Valsartan/hydrochlorothiazide has been shown to be an efficacious fixed-dose combination antihypertensive agent that is well tolerated with few side effects.
No takes yet. Share an insight, caveat, or question.
Kondrack et al. (2009) conducted a review in Hypertension. Valsartan/hydrochlorothiazide vs. Individual components and amlodipine was evaluated. Valsartan/hydrochlorothiazide is an efficacious fixed-dose combination antihypertensive agent that is superior to its individual components and has similar morbidity and mortality outcomes to amlodipine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: